TNK2 and neoplasm: Further mechanistic studies revealed that targeting ACK1 kinase may be a holistic therapeutic strategy to mitigate PCa due to the multi-functional role of ACK1 in tumor initiation and progression and as an effector of acetylated HOXB13, an oncogenic transcription factor associated with CRPC development.4